BTL Expands EXOMIND® Platform with New FDA Clearances

MARLBOROUGH, Mass., Oct. 1, 2026 /CourierPR/ -- BTL Industries, a global leader in medical and wellness technologies, has expanded its EXOMIND® platform with new FDA clearances, marking a significant step in its mission to provide innovative solutions for mental health conditions. The company first entered the U.S. market in 2025 with EXOMIND® for the treatment of major depressive disorder (MDD) in adult patients. Now, the platform has been cleared for additional uses, including obsessive-compulsive disorder (OCD), MDD comorbid anxiety, and care for adolescent patients (15-21 years).

EXOMIND® now offers an intermittent theta burst protocol, allowing treatment sessions as short as three minutes. This new feature is designed to make care more accessible and convenient for patients, as well as for healthcare providers. Dr. Dennis Weimer, a physician triple board-certified in Psychiatry, Consultation-Liaison Psychiatry, and Addiction Medicine, commented on the impact of EXOMIND® on his practice.

The new EXOMIND® Dual Applicator further enhances the platform's capabilities, providing greater flexibility to personalize patient care. Dr. Michelle Dees, a board-certified psychiatrist, highlighted the importance of these new clearances.

BTL Industries, founded in 1993, is committed to expanding the capabilities of EXOMIND® and increasing access to care. The company has more than 200 patents and over 600 in-house engineers, using technology and science to advance medical treatments. EXOMIND® is a core part of BTL's portfolio, and the company will continue to invest in its future.

To celebrate these advancements, BTL will host North American EXOMIND® Days from October 13 to 15, 2026. Over three days, practices and communities will share real experiences, introduce new possibilities, and create space for people to take the next step toward feeling calmer, more confident, and more in control.